There is evidence that individuals with an early hyperinflammatory phenotype and organ damage in the second week following the beginning of symptoms may benefit primarily from inhibiting the IL-6 in terms of treating this sort of excessive inflammatory response in COVID-19. The gene discussed is IL6; the disease is COVID-19.